Global Hormonal Contraceptive Market Size by Product (Combined Oral Contraceptives, Oral Contraceptives, Injectable Contraceptives, Implantable Contraceptives, Intrauterine (IUD), Transdermal Patch and Vaginal Rings), By End-use (Hospitals, Clinics, Households) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027

Report ID :AMI-260 | Category : Healthcare | Published Date : August, 2019 | Pages : 255 | Format :PDF
Buy Now!

Industry Trends

Global Hormonal Contraceptive Market was valued at USD 19,759.0 million in 2018 and is estimated to reach USD 28,690.0 million by 2027, growing at a CAGR of 4.2% over the forecast period.

Global Hormonal Contraceptive Market Revenue, 2015 - 2027

Global Hormonal Contraceptive Market

There has been a rapid ride of unintended pregnancies and trauma and cost of abortions along with improved technology and heightened awareness among people has propelled the growth of hormonal contraceptives market in the world. Technology to prevent pregnancy with minimum damage and side effects is being conceptualized and developed as we speak. With pro life calls in certain countries and stark opposition, the market does possess its share of threats, but the overall climate globally and increasing governmental intervention and initiatives, Hormonal contraceptives are here to stay.

Pharmaceutical giants like Allegran, Teva and Bayer Inc. have been at the forefront of not only creating safer and more effective hormonal contraceptive methods, but also participating by associating in socially charged initiatives to help increase awareness and use of these contraceptives, thus consolidating their position in the market.

United Nations announced 26 September, as World Contraception Day, to be celebrated every year. According to a report that was published by the World Contraception Day Coalition Committee powered by United Nations, more than 41% of the 208 million pregnancies that occur each year are unplanned, most of which result in abortions. More than 30 million of these recorded unintended pregnancies happen due to failure of contraceptive or erroneous use. The same also has resulted in increasing mortality among women, largely aged between 15- 19 years. Evolving Contraception methods have the potential to avoid unplanned pregnancies and thus abortions and consequent deaths. Developing countries have witnessed this negative surge and a combined figure surpassing 800 million have expressed concern over possible pregnancies they want to avoid. There is augmenting need and scope for the contraceptive market to grow and thrive. Research, policy effort, private involvement and general awareness, that now fueling growth in the hormonal contraceptive market in developed countries, needs acceleration with respect to emerging and developing economies.

Countries around the world are actively participating, with changes in existing policies to accommodate women’s healthcare and safety needs. Hormonal contraception is being adopted increasingly by people. Combined Oral Contraceptives, Oral Contraceptives, Injectable Contraceptives, Implantable Contraceptives, Intrauterine (IUD), Transdermal Patch and Vaginal Rings are the various methods that have seen many structural changes in the last few decades. These methods are further divided on the basis of hormones; progestin only and combined estrogen and progestin and its varying representations applications. There is also a stiff competition between these products with some have more effectual results with lesser side effects, over another. Their country wise landscape also varied.

Oral (Combined) hormonal contraceptive method has been the most opted for in the world, with US taking precedence in its introduction and usage. This method that prevents pregnancy is not without apparent side effects, thus driving the global hormonal contraceptive market. Reports on dangers associated with Oral hormonal contraception, have increased the administration of IUD and vaginal rings. Injective and patch hormonal contraceptives are more prevalent in African countries when compared to North American, Europe, Asia Pacific and Middle Eastern Regions.

Most of the Hormonal Contraceptive Products are available at the prescription of the physician, with the exception, especially emergency contraceptive pills, that have found wide recognition through media and television ads. There is a strong demand for developing hormonal contraception that affords easy availability and is cost effective. This in turn is advancing channelized growth for the hormonal contraceptive market.

Many countries with inherent moral dilemma are still facing issues with contraception. Countries like China and India, need the most attention with contraception with their rapid increase in population. There is also a very ambivalent reaction to hormonal contraception in US, with some states rallying against in amid increasing protests from factions to make contraception and easy availability. There is also parallel development in the male hormonal contraception arena, that is still under progress.

North America hormonal contraceptive market continues to be the largest for hormonal contraceptives in the world, with a rate of 99% success witnessed among the users of oral contraception. US alone takes the largest market share. Middle East and Africa have also shown a steady increase owing to more exposure and better designated attempts to counter problems like infertility, lifestyle disorders, obesity and more aided with the entry of global key players.

The report provides both, qualitative and quantitative research of global hormonal contraceptive market, it also provides penetrative insights into the rational scenario and favored development methods adopted by key contenders. The report also offers extensive research on the key players in the market and detailed insights into the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by major players are also recognized and analyzed in the report. For each company, the report recognizes its headquarters, competitors, product/service type, application and specification, pricing, and gross margin.

Competitive Landscape

Major industry participants in Hormonal Contraceptive market include. Allergan, Bayer Pharmaceuticals that provide Long-acting reversible contraception using intrauterine delivery systems (IUS). Cipla, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd (RAJANI- a generic version of Beyaz), Novartis and Piramal pharma Solutions, provide oral hormonal contraceptives pills. The patch market is confined to Evra, marketed in Canada by Janssen-Ortho and in the United Kingdom and other countries by Janssen-Cilag and Xulane in the United States. New product launches, geographical expansions are some of the major strategies adopted by these players to gain a competitive edge.

By Method: 

  • Combined oral contraceptives
  • Oral contraceptives
  • Injectable contraceptives
  • Implantable contraceptives
  • Intrauterine
  • Transdermal patch
  • Vaginal rings

By Hormones:

  • Androgen
  • Estrogen
  • Progestogens
  • Gonadotropins
  • Antiandrogens
  • Others

By End User

  • Hospitals
  • Clinics
  • Households
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
    • Benelux Union
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Argentina
    • Brazil
    • Rest of Latin America

Key Questions

Request Sample

Report Customization

Request for Customization

1.    Market Scope

1.1.   Market Segmentation

1.2.   Years Considered

1.2.1.   Historic Years: 2013 - 2017

1.2.2.   Base Year: 2018

1.2.3.   Forecast Years: 2019 – 2027

2.    Key Target Audiences

3.    Research Methodology

3.1.   Primary Research

3.1.1.   Research Questionnaire

3.1.2.   Global Percentage Breakdown

3.1.3.   Primary Interviews: Key Opinion Leaders (KOLs)

3.2.   Secondary Research

3.2.1.   Paid Databases

3.2.2.   Secondary Sources

3.3.   Market Size Estimates

3.3.1.   Top-Down Approach

3.3.2.   Bottom-Up Approach

3.4.   Data Triangulation Methodology

3.5.   Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of Hormonal Contraceptive Market

6.    Market Synopsis:  Hormonal Contraceptive Market

7.    Hormonal Contraceptive Market Analysis: Qualitative Perspective

7.1.   Introduction

7.1.1.   Product Definition

7.1.2.   Industry Development

7.2.   Market Dynamics

7.2.1.   Drivers

7.2.2.   Restraints

7.2.3.   Opportunities

7.3.   Trends in Hormonal Contraceptive Market

7.4.   Market Determinants Radar Chart

7.5.   Macro-Economic and Micro-Economic Indicators: Hormonal Contraceptive Market

7.6.   Industry Gross Margin Overview

7.7.   Porter’s Five Force Analysis

8.    Global Hormonal Contraceptive Market Analysis and Forecasts, 2019 – 2027

8.1.   Overview

8.1.1.   Global Hormonal Contraceptive Market Revenue (US$ Mn)

8.2.   Global Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

8.2.1.   Combined oral contraceptives

8.2.1.1.    Definition

8.2.1.2.    Market Penetration, 2018

8.2.1.3.    Market Estimation, 2013 – 2018

8.2.1.4.    Market Forecast, 2019 – 2027

8.2.1.5.    Compound Annual Growth Rate (CAGR)

8.2.1.6.    Regional Bifurcation

8.2.1.6.1.    North America

8.2.1.6.1.1.  Market Estimation, 2013 – 2018

8.2.1.6.1.2.  Market Forecast, 2019 – 2027

8.2.1.6.2.    Europe

8.2.1.6.2.1.  Market Estimation, 2013 – 2018

8.2.1.6.2.2.  Market Forecast, 2019 – 2027

8.2.1.6.3.    Asia Pacific

8.2.1.6.3.1.  Market Estimation, 2013 – 2018

8.2.1.6.3.2.  Market Forecast, 2019 – 2027

8.2.1.6.4.    Middle East and Africa

8.2.1.6.4.1.  Market Estimation, 2013 – 2018

8.2.1.6.4.2.  Market Forecast, 2019 – 2027

8.2.1.6.5.    Latin America

8.2.1.6.5.1.  Market Estimation, 2013 – 2018

8.2.1.6.5.2.  Market Forecast, 2019 – 2027

8.2.2.   Oral contraceptives

8.2.2.1.    Definition

8.2.2.2.    Market Penetration, 2018

8.2.2.3.    Market Estimation, 2013 – 2018

8.2.2.4.    Market Forecast, 2019 – 2027

8.2.2.5.    Compound Annual Growth Rate (CAGR)

8.2.2.6.    Regional Bifurcation

8.2.2.6.1.    North America

8.2.2.6.1.1.  Market Estimation, 2013 – 2018

8.2.2.6.1.2.  Market Forecast, 2019 – 2027

8.2.2.6.2.    Europe

8.2.2.6.2.1.  Market Estimation, 2013 – 2018

8.2.2.6.2.2.  Market Forecast, 2019 – 2027

8.2.2.6.3.    Asia Pacific

8.2.2.6.3.1.  Market Estimation, 2013 – 2018

8.2.2.6.3.2.  Market Forecast, 2019 – 2027

8.2.2.6.4.    Middle East and Africa

8.2.2.6.4.1.  Market Estimation, 2013 – 2018

8.2.2.6.4.2.  Market Forecast, 2019 – 2027

8.2.2.6.5.    Latin America

8.2.2.6.5.1.  Market Estimation, 2013 – 2018

8.2.2.6.5.2.  Market Forecast, 2019 – 2027

8.2.3.   Injectable contraceptives

8.2.3.1.    Definition

8.2.3.2.    Market Penetration, 2018

8.2.3.3.    Market Estimation, 2013 – 2018

8.2.3.4.    Market Forecast, 2019 – 2027

8.2.3.5.    Compound Annual Growth Rate (CAGR)

8.2.3.6.    Regional Bifurcation

8.2.3.6.1.    North America

8.2.3.6.1.1.  Market Estimation, 2013 – 2018

8.2.3.6.1.2.  Market Forecast, 2019 – 2027

8.2.3.6.2.    Europe

8.2.3.6.2.1.  Market Estimation, 2013 – 2018

8.2.3.6.2.2.  Market Forecast, 2019 – 2027

8.2.3.6.3.    Asia Pacific

8.2.3.6.3.1.  Market Estimation, 2013 – 2018

8.2.3.6.3.2.  Market Forecast, 2019 – 2027

8.2.3.6.4.    Middle East and Africa

8.2.3.6.4.1.  Market Estimation, 2013 – 2018

8.2.3.6.4.2.  Market Forecast, 2019 – 2027

8.2.3.6.5.    Latin America

8.2.3.6.5.1.  Market Estimation, 2013 – 2018

8.2.3.6.5.2.  Market Forecast, 2019 – 2027

8.2.4.   Implantable contraceptives

8.2.4.1.    Definition

8.2.4.2.    Market Penetration, 2018

8.2.4.3.    Market Estimation, 2013 – 2018

8.2.4.4.    Market Forecast, 2019 – 2027

8.2.4.5.    Compound Annual Growth Rate (CAGR)

8.2.4.6.    Regional Bifurcation

8.2.4.6.1.    North America

8.2.4.6.1.1.  Market Estimation, 2013 – 2018

8.2.4.6.1.2.  Market Forecast, 2019 – 2027

8.2.4.6.2.    Europe

8.2.4.6.2.1.  Market Estimation, 2013 – 2018

8.2.4.6.2.2.  Market Forecast, 2019 – 2027

8.2.4.6.3.    Asia Pacific

8.2.4.6.3.1.  Market Estimation, 2013 – 2018

8.2.4.6.3.2.  Market Forecast, 2019 – 2027

8.2.4.6.4.    Middle East and Africa

8.2.4.6.4.1.  Market Estimation, 2013 – 2018

8.2.4.6.4.2.  Market Forecast, 2019 – 2027

8.2.4.6.5.    Latin America

8.2.4.6.5.1.  Market Estimation, 2013 – 2018

8.2.4.6.5.2.  Market Forecast, 2019 – 2027

8.2.5.   Intrauterine

8.2.5.1.    Definition

8.2.5.2.    Market Penetration, 2018

8.2.5.3.    Market Estimation, 2013 – 2018

8.2.5.4.    Market Forecast, 2019 – 2027

8.2.5.5.    Compound Annual Growth Rate (CAGR)

8.2.5.6.    Regional Bifurcation

8.2.5.6.1.    North America

8.2.5.6.1.1.  Market Estimation, 2013 – 2018

8.2.5.6.1.2.  Market Forecast, 2019 – 2027

8.2.5.6.2.    Europe

8.2.5.6.2.1.  Market Estimation, 2013 – 2018

8.2.5.6.2.2.  Market Forecast, 2019 – 2027

8.2.5.6.3.    Asia Pacific

8.2.5.6.3.1.  Market Estimation, 2013 – 2018

8.2.5.6.3.2.  Market Forecast, 2019 – 2027

8.2.5.6.4.    Middle East and Africa

8.2.5.6.4.1.  Market Estimation, 2013 – 2018

8.2.5.6.4.2.  Market Forecast, 2019 – 2027

8.2.5.6.5.    Latin America

8.2.5.6.5.1.  Market Estimation, 2013 – 2018

8.2.5.6.5.2.  Market Forecast, 2019 – 2027

8.2.6.   Transdermal patch

8.2.6.1.    Definition

8.2.6.2.    Market Penetration, 2018

8.2.6.3.    Market Estimation, 2013 – 2018

8.2.6.4.    Market Forecast, 2019 – 2027

8.2.6.5.    Compound Annual Growth Rate (CAGR)

8.2.6.6.    Regional Bifurcation

8.2.6.6.1.    North America

8.2.6.6.1.1.  Market Estimation, 2013 – 2018

8.2.6.6.1.2.  Market Forecast, 2019 – 2027

8.2.6.6.2.    Europe

8.2.6.6.2.1.  Market Estimation, 2013 – 2018

8.2.6.6.2.2.  Market Forecast, 2019 – 2027

8.2.6.6.3.    Asia Pacific

8.2.6.6.3.1.  Market Estimation, 2013 – 2018

8.2.6.6.3.2.  Market Forecast, 2019 – 2027

8.2.6.6.4.    Middle East and Africa

8.2.6.6.4.1.  Market Estimation, 2013 – 2018

8.2.6.6.4.2.  Market Forecast, 2019 – 2027

8.2.6.6.5.    Latin America

8.2.6.6.5.1.  Market Estimation, 2013 – 2018

8.2.6.6.5.2.  Market Forecast, 2019 – 2027

8.2.7.   Vaginal rings

8.2.7.1.    Definition

8.2.7.2.    Market Penetration, 2018

8.2.7.3.    Market Estimation, 2013 – 2018

8.2.7.4.    Market Forecast, 2019 – 2027

8.2.7.5.    Compound Annual Growth Rate (CAGR)

8.2.7.6.    Regional Bifurcation

8.2.7.6.1.    North America

8.2.7.6.1.1.  Market Estimation, 2013 – 2018

8.2.7.6.1.2.  Market Forecast, 2019 – 2027

8.2.7.6.2.    Europe

8.2.7.6.2.1.  Market Estimation, 2013 – 2018

8.2.7.6.2.2.  Market Forecast, 2019 – 2027

8.2.7.6.3.    Asia Pacific

8.2.7.6.3.1.  Market Estimation, 2013 – 2018

8.2.7.6.3.2.  Market Forecast, 2019 – 2027

8.2.7.6.4.    Middle East and Africa

8.2.7.6.4.1.  Market Estimation, 2013 – 2018

8.2.7.6.4.2.  Market Forecast, 2019 – 2027

8.2.7.6.5.    Latin America

8.2.7.6.5.1.  Market Estimation, 2013 – 2018

8.2.7.6.5.2.  Market Forecast, 2019 – 2027

8.3.   Key Segment for Channeling Investments

8.3.1.   By Method

9.    Global Hormonal Contraceptive Market Analysis and Forecasts, 2019 – 2027

9.1.   Overview

9.2.   Global Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

9.2.1.   Androgen

9.2.1.1.    Definition

9.2.1.2.    Market Penetration, 2018

9.2.1.3.    Market Estimation, 2013 – 2018

9.2.1.4.    Market Forecast, 2019 – 2027

9.2.1.5.    Compound Annual Growth Rate (CAGR)

9.2.1.6.    Regional Bifurcation

9.2.1.6.1.    North America

9.2.1.6.1.1.  Market Estimation, 2013 – 2018

9.2.1.6.1.2.  Market Forecast, 2019 – 2027

9.2.1.6.2.    Europe

9.2.1.6.2.1.  Market Estimation, 2013 – 2018

9.2.1.6.2.2.  Market Forecast, 2019 – 2027

9.2.1.6.3.    Asia Pacific

9.2.1.6.3.1.  Market Estimation, 2013 – 2018

9.2.1.6.3.2.  Market Forecast, 2019 – 2027

9.2.1.6.4.    Middle East and Africa

9.2.1.6.4.1.  Market Estimation, 2013 – 2018

9.2.1.6.4.2.  Market Forecast, 2019 – 2027

9.2.1.6.5.    Latin America

9.2.1.6.5.1.  Market Estimation, 2013 – 2018

9.2.1.6.5.2.  Market Forecast, 2019 – 2027

9.2.2.   Estrogen

9.2.2.1.    Definition

9.2.2.2.    Market Penetration, 2018

9.2.2.3.    Market Estimation, 2013 – 2018

9.2.2.4.    Market Forecast, 2019 – 2027

9.2.2.5.    Compound Annual Growth Rate (CAGR)

9.2.2.6.    Regional Bifurcation

9.2.2.6.1.    North America

9.2.2.6.1.1.  Market Estimation, 2013 – 2018

9.2.2.6.1.2.  Market Forecast, 2019 – 2027

9.2.2.6.2.    Europe

9.2.2.6.2.1.  Market Estimation, 2013 – 2018

9.2.2.6.2.2.  Market Forecast, 2019 – 2027

9.2.2.6.3.    Asia Pacific

9.2.2.6.3.1.  Market Estimation, 2013 – 2018

9.2.2.6.3.2.  Market Forecast, 2019 – 2027

9.2.2.6.4.    Middle East and Africa

9.2.2.6.4.1.  Market Estimation, 2013 – 2018

9.2.2.6.4.2.  Market Forecast, 2019 – 2027

9.2.2.6.5.    Latin America

9.2.2.6.5.1.  Market Estimation, 2013 – 2018

9.2.2.6.5.2.  Market Forecast, 2019 – 2027

9.2.3.   Progestogens

9.2.3.1.    Definition

9.2.3.2.    Market Penetration, 2018

9.2.3.3.    Market Estimation, 2013 – 2018

9.2.3.4.    Market Forecast, 2019 – 2027

9.2.3.5.    Compound Annual Growth Rate (CAGR)

9.2.3.6.    Regional Bifurcation

9.2.3.6.1.    North America

9.2.3.6.1.1.  Market Estimation, 2013 – 2018

9.2.3.6.1.2.  Market Forecast, 2019 – 2027

9.2.3.6.2.    Europe

9.2.3.6.2.1.  Market Estimation, 2013 – 2018

9.2.3.6.2.2.  Market Forecast, 2019 – 2027

9.2.3.6.3.    Asia Pacific

9.2.3.6.3.1.  Market Estimation, 2013 – 2018

9.2.3.6.3.2.  Market Forecast, 2019 – 2027

9.2.3.6.4.    Middle East and Africa

9.2.3.6.4.1.  Market Estimation, 2013 – 2018

9.2.3.6.4.2.  Market Forecast, 2019 – 2027

9.2.3.6.5.    Latin America

9.2.3.6.5.1.  Market Estimation, 2013 – 2018

9.2.3.6.5.2.  Market Forecast, 2019 – 2027

9.2.4.   Gonadotropins

9.2.4.1.    Definition

9.2.4.2.    Market Penetration, 2018

9.2.4.3.    Market Estimation, 2013 – 2018

9.2.4.4.    Market Forecast, 2019 – 2027

9.2.4.5.    Compound Annual Growth Rate (CAGR)

9.2.4.6.    Regional Bifurcation

9.2.4.6.1.    North America

9.2.4.6.1.1.  Market Estimation, 2013 – 2018

9.2.4.6.1.2.  Market Forecast, 2019 – 2027

9.2.4.6.2.    Europe

9.2.4.6.2.1.  Market Estimation, 2013 – 2018

9.2.4.6.2.2.  Market Forecast, 2019 – 2027

9.2.4.6.3.    Asia Pacific

9.2.4.6.3.1.  Market Estimation, 2013 – 2018

9.2.4.6.3.2.  Market Forecast, 2019 – 2027

9.2.4.6.4.    Middle East and Africa

9.2.4.6.4.1.  Market Estimation, 2013 – 2018

9.2.4.6.4.2.  Market Forecast, 2019 – 2027

9.2.4.6.5.    Latin America

9.2.4.6.5.1.  Market Estimation, 2013 – 2018

9.2.4.6.5.2.  Market Forecast, 2019 – 2027

9.2.5.   Antiandrogens

9.2.5.1.    Definition

9.2.5.2.    Market Penetration, 2018

9.2.5.3.    Market Estimation, 2013 – 2018

9.2.5.4.    Market Forecast, 2019 – 2027

9.2.5.5.    Compound Annual Growth Rate (CAGR)

9.2.5.6.    Regional Bifurcation

9.2.5.6.1.    North America

9.2.5.6.1.1.  Market Estimation, 2013 – 2018

9.2.5.6.1.2.  Market Forecast, 2019 – 2027

9.2.5.6.2.    Europe

9.2.5.6.2.1.  Market Estimation, 2013 – 2018

9.2.5.6.2.2.  Market Forecast, 2019 – 2027

9.2.5.6.3.    Asia Pacific

9.2.5.6.3.1.  Market Estimation, 2013 – 2018

9.2.5.6.3.2.  Market Forecast, 2019 – 2027

9.2.5.6.4.    Middle East and Africa

9.2.5.6.4.1.  Market Estimation, 2013 – 2018

9.2.5.6.4.2.  Market Forecast, 2019 – 2027

9.2.5.6.5.    Latin America

9.2.5.6.5.1.  Market Estimation, 2013 – 2018

9.2.5.6.5.2.  Market Forecast, 2019 – 2027

9.2.6.   Others

9.2.6.1.    Definition

9.2.6.2.    Market Penetration, 2018

9.2.6.3.    Market Estimation, 2013 – 2018

9.2.6.4.    Market Forecast, 2019 – 2027

9.2.6.5.    Compound Annual Growth Rate (CAGR)

9.2.6.6.    Regional Bifurcation

9.2.6.6.1.    North America

9.2.6.6.1.1.  Market Estimation, 2013 – 2018

9.2.6.6.1.2.  Market Forecast, 2019 – 2027

9.2.6.6.2.    Europe

9.2.6.6.2.1.  Market Estimation, 2013 – 2018

9.2.6.6.2.2.  Market Forecast, 2019 – 2027

9.2.6.6.3.    Asia Pacific

9.2.6.6.3.1.  Market Estimation, 2013 – 2018

9.2.6.6.3.2.  Market Forecast, 2019 – 2027

9.2.6.6.4.    Middle East and Africa

9.2.6.6.4.1.  Market Estimation, 2013 – 2018

9.2.6.6.4.2.  Market Forecast, 2019 – 2027

9.2.6.6.5.    Latin America

9.2.6.6.5.1.  Market Estimation, 2013 – 2018

9.2.6.6.5.2.  Market Forecast, 2019 – 2027

9.3.   Key Segment for Channeling Investments

9.3.1.   By Hormones

10. North America Hormonal Contraceptive Market Analysis and Forecasts, 2019 - 2027

10.1. Overview

10.1.1. North America Hormonal Contraceptive Market Revenue (US$ Mn)

10.2. North America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

10.2.1. Combined oral contraceptives

10.2.2. Oral contraceptives

10.2.3. Injectable contraceptives

10.2.4. Implantable contraceptives

10.2.5. Intrauterine

10.2.6. Transdermal patch

10.2.7. Vaginal rings

10.3. North America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

10.3.1. Androgen

10.3.2. Estrogen

10.3.3. Progestogens

10.3.4. Gonadotropins

10.3.5. Antiandrogens

10.3.6. Others

10.4. North America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. U.S

10.4.1.1.  U.S Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

10.4.1.1.1.  Combined oral contraceptives

10.4.1.1.2.  Oral contraceptives

10.4.1.1.3.  Injectable contraceptives

10.4.1.1.4.  Implantable contraceptives

10.4.1.1.5.  Intrauterine

10.4.1.1.6.  Transdermal patch

10.4.1.1.7.  Vaginal rings

10.4.1.2.  U.S Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

10.4.1.2.1.  Androgen

10.4.1.2.2.  Estrogen

10.4.1.2.3.  Progestogens

10.4.1.2.4.  Gonadotropins

10.4.1.2.5.  Antiandrogens

10.4.1.2.6.  Others

10.4.2. Canada

10.4.2.1.  Canada Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

10.4.2.1.1.  Combined oral contraceptives

10.4.2.1.2.  Oral contraceptives

10.4.2.1.3.  Injectable contraceptives

10.4.2.1.4.  Implantable contraceptives

10.4.2.1.5.  Intrauterine

10.4.2.1.6.  Transdermal patch

10.4.2.1.7.  Vaginal rings

10.4.2.2.  Canada Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

10.4.2.2.1.  Androgen

10.4.2.2.2.  Estrogen

10.4.2.2.3.  Progestogens

10.4.2.2.4.  Gonadotropins

10.4.2.2.5.  Antiandrogens

10.4.2.2.6.  Others

10.4.3. Mexico

10.4.3.1.  Mexico Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

10.4.3.1.1.  Combined oral contraceptives

10.4.3.1.2.  Oral contraceptives

10.4.3.1.3.  Injectable contraceptives

10.4.3.1.4.  Implantable contraceptives

10.4.3.1.5.  Intrauterine

10.4.3.1.6.  Transdermal patch

10.4.3.1.7.  Vaginal rings

10.4.3.2.  Mexico Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

10.4.3.2.1.  Androgen

10.4.3.2.2.  Estrogen

10.4.3.2.3.  Progestogens

10.4.3.2.4.  Gonadotropins

10.4.3.2.5.  Antiandrogens

10.4.3.2.6.  Others

10.4.4. Rest of North America

10.4.4.1.  Rest of North America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

10.4.4.1.1.  Combined oral contraceptives

10.4.4.1.2.  Oral contraceptives

10.4.4.1.3.  Injectable contraceptives

10.4.4.1.4.  Implantable contraceptives

10.4.4.1.5.  Intrauterine

10.4.4.1.6.  Transdermal patch

10.4.4.1.7.  Vaginal rings

10.4.4.2.  Rest of North America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

10.4.4.2.1.  Androgen

10.4.4.2.2.  Estrogen

10.4.4.2.3.  Progestogens

10.4.4.2.4.  Gonadotropins

10.4.4.2.5.  Antiandrogens

10.4.4.2.6.  Others

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Method

10.5.3. By Hormones

11. Europe Hormonal Contraceptive Market Analysis and Forecasts, 2019 - 2027

11.1. Overview

11.1.1. Europe Hormonal Contraceptive Market Revenue (US$ Mn)

11.2. Europe Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.2.1. Combined oral contraceptives

11.2.2. Oral contraceptives

11.2.3. Injectable contraceptives

11.2.4. Implantable contraceptives

11.2.5. Intrauterine

11.2.6. Transdermal patch

11.2.7. Vaginal rings

11.3. Europe Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.3.1. Androgen

11.3.2. Estrogen

11.3.3. Progestogens

11.3.4. Gonadotropins

11.3.5. Antiandrogens

11.3.6. Others

11.4. Europe Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. France

11.4.1.1.  France Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.1.1.1.  Combined oral contraceptives

11.4.1.1.2.  Oral contraceptives

11.4.1.1.3.  Injectable contraceptives

11.4.1.1.4.  Implantable contraceptives

11.4.1.1.5.  Intrauterine

11.4.1.1.6.  Transdermal patch

11.4.1.1.7.  Vaginal rings

11.4.1.2.  France Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.1.2.1.  Androgen

11.4.1.2.2.  Estrogen

11.4.1.2.3.  Progestogens

11.4.1.2.4.  Gonadotropins

11.4.1.2.5.  Antiandrogens

11.4.1.2.6.  Others

11.4.2. The UK

11.4.2.1.  The UK Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.2.1.1.  Combined oral contraceptives

11.4.2.1.2.  Oral contraceptives

11.4.2.1.3.  Injectable contraceptives

11.4.2.1.4.  Implantable contraceptives

11.4.2.1.5.  Intrauterine

11.4.2.1.6.  Transdermal patch

11.4.2.1.7.  Vaginal rings

11.4.2.2.  The UK Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.2.2.1.  Androgen

11.4.2.2.2.  Estrogen

11.4.2.2.3.  Progestogens

11.4.2.2.4.  Gonadotropins

11.4.2.2.5.  Antiandrogens

11.4.2.2.6.  Others

11.4.3. Spain

11.4.3.1.  Spain Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.3.1.1.  Combined oral contraceptives

11.4.3.1.2.  Oral contraceptives

11.4.3.1.3.  Injectable contraceptives

11.4.3.1.4.  Implantable contraceptives

11.4.3.1.5.  Intrauterine

11.4.3.1.6.  Transdermal patch

11.4.3.1.7.  Vaginal rings

11.4.3.2.  Spain Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.3.2.1.  Androgen

11.4.3.2.2.  Estrogen

11.4.3.2.3.  Progestogens

11.4.3.2.4.  Gonadotropins

11.4.3.2.5.  Antiandrogens

11.4.3.2.6.  Others

11.4.4. Germany

11.4.4.1.  Germany Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.4.1.1.  Combined oral contraceptives

11.4.4.1.2.  Oral contraceptives

11.4.4.1.3.  Injectable contraceptives

11.4.4.1.4.  Implantable contraceptives

11.4.4.1.5.  Intrauterine

11.4.4.1.6.  Transdermal patch

11.4.4.1.7.  Vaginal rings

11.4.4.2.  Germany Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.4.2.1.  Androgen

11.4.4.2.2.  Estrogen

11.4.4.2.3.  Progestogens

11.4.4.2.4.  Gonadotropins

11.4.4.2.5.  Antiandrogens

11.4.4.2.6.  Others

11.4.5. Italy

11.4.5.1.  Italy Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.5.1.1.  Combined oral contraceptives

11.4.5.1.2.  Oral contraceptives

11.4.5.1.3.  Injectable contraceptives

11.4.5.1.4.  Implantable contraceptives

11.4.5.1.5.  Intrauterine

11.4.5.1.6.  Transdermal patch

11.4.5.1.7.  Vaginal rings

11.4.5.2.  Italy Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.5.2.1.  Androgen

11.4.5.2.2.  Estrogen

11.4.5.2.3.  Progestogens

11.4.5.2.4.  Gonadotropins

11.4.5.2.5.  Antiandrogens

11.4.5.2.6.  Others

11.4.6. Nordic Countries

11.4.6.1.  Nordic Countries Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.6.1.1.  Combined oral contraceptives

11.4.6.1.2.  Oral contraceptives

11.4.6.1.3.  Injectable contraceptives

11.4.6.1.4.  Implantable contraceptives

11.4.6.1.5.  Intrauterine

11.4.6.1.6.  Transdermal patch

11.4.6.1.7.  Vaginal rings

11.4.6.2.  Nordic Countries Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.6.2.1.  Androgen

11.4.6.2.2.  Estrogen

11.4.6.2.3.  Progestogens

11.4.6.2.4.  Gonadotropins

11.4.6.2.5.  Antiandrogens

11.4.6.2.6.  Others

11.4.6.3.  Nordic Countries Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

11.4.6.3.1.  Denmark

11.4.6.3.2.  Finland

11.4.6.3.3.  Iceland

11.4.6.3.4.  Sweden

11.4.6.3.5.  Norway

11.4.7. Benelux Union

11.4.7.1.  Benelux Union Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.7.1.1.  Combined oral contraceptives

11.4.7.1.2.  Oral contraceptives

11.4.7.1.3.  Injectable contraceptives

11.4.7.1.4.  Implantable contraceptives

11.4.7.1.5.  Intrauterine

11.4.7.1.6.  Transdermal patch

11.4.7.1.7.  Vaginal rings

11.4.7.2.  Benelux Union Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.7.2.1.  Androgen

11.4.7.2.2.  Estrogen

11.4.7.2.3.  Progestogens

11.4.7.2.4.  Gonadotropins

11.4.7.2.5.  Antiandrogens

11.4.7.2.6.  Others

11.4.7.3.  Benelux Union Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

11.4.7.3.1.  Belgium

11.4.7.3.2.  The Netherlands

11.4.7.3.3.  Luxembourg

11.4.8. Rest of Europe

11.4.8.1.  Rest of Europe Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

11.4.8.1.1.  Combined oral contraceptives

11.4.8.1.2.  Oral contraceptives

11.4.8.1.3.  Injectable contraceptives

11.4.8.1.4.  Implantable contraceptives

11.4.8.1.5.  Intrauterine

11.4.8.1.6.  Transdermal patch

11.4.8.1.7.  Vaginal rings

11.4.8.2.  Rest of Europe Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

11.4.8.2.1.  Androgen

11.4.8.2.2.  Estrogen

11.4.8.2.3.  Progestogens

11.4.8.2.4.  Gonadotropins

11.4.8.2.5.  Antiandrogens

11.4.8.2.6.  Others

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Method

11.5.3. By Hormones

12. Asia Pacific Hormonal Contraceptive Market Analysis and Forecasts, 2019 - 2027

12.1. Overview

12.1.1. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn)

12.2. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.2.1. Combined oral contraceptives

12.2.2. Oral contraceptives

12.2.3. Injectable contraceptives

12.2.4. Implantable contraceptives

12.2.5. Intrauterine

12.2.6. Transdermal patch

12.2.7. Vaginal rings

12.3. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.3.1. Androgen

12.3.2. Estrogen

12.3.3. Progestogens

12.3.4. Gonadotropins

12.3.5. Antiandrogens

12.3.6. Others

12.4. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

12.4.1. China

12.4.1.1.  China Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.1.1.1.  Combined oral contraceptives

12.4.1.1.2.  Oral contraceptives

12.4.1.1.3.  Injectable contraceptives

12.4.1.1.4.  Implantable contraceptives

12.4.1.1.5.  Intrauterine

12.4.1.1.6.  Transdermal patch

12.4.1.1.7.  Vaginal rings

12.4.1.2.  China Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.1.2.1.  Androgen

12.4.1.2.2.  Estrogen

12.4.1.2.3.  Progestogens

12.4.1.2.4.  Gonadotropins

12.4.1.2.5.  Antiandrogens

12.4.1.2.6.  Others

12.4.2. Japan

12.4.2.1.  Japan Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.2.1.1.  Combined oral contraceptives

12.4.2.1.2.  Oral contraceptives

12.4.2.1.3.  Injectable contraceptives

12.4.2.1.4.  Implantable contraceptives

12.4.2.1.5.  Intrauterine

12.4.2.1.6.  Transdermal patch

12.4.2.1.7.  Vaginal rings

12.4.2.2.  Japan Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.2.2.1.  Androgen

12.4.2.2.2.  Estrogen

12.4.2.2.3.  Progestogens

12.4.2.2.4.  Gonadotropins

12.4.2.2.5.  Antiandrogens

12.4.2.2.6.  Others

12.4.3. India

12.4.3.1.  India Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.3.1.1.  Combined oral contraceptives

12.4.3.1.2.  Oral contraceptives

12.4.3.1.3.  Injectable contraceptives

12.4.3.1.4.  Implantable contraceptives

12.4.3.1.5.  Intrauterine

12.4.3.1.6.  Transdermal patch

12.4.3.1.7.  Vaginal rings

12.4.3.2.  India Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.3.2.1.  Androgen

12.4.3.2.2.  Estrogen

12.4.3.2.3.  Progestogens

12.4.3.2.4.  Gonadotropins

12.4.3.2.5.  Antiandrogens

12.4.3.2.6.  Others

12.4.4. New Zealand

12.4.4.1.  New Zealand Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.4.1.1.  Combined oral contraceptives

12.4.4.1.2.  Oral contraceptives

12.4.4.1.3.  Injectable contraceptives

12.4.4.1.4.  Implantable contraceptives

12.4.4.1.5.  Intrauterine

12.4.4.1.6.  Transdermal patch

12.4.4.1.7.  Vaginal rings

12.4.4.2.  New Zealand Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.4.2.1.  Androgen

12.4.4.2.2.  Estrogen

12.4.4.2.3.  Progestogens

12.4.4.2.4.  Gonadotropins

12.4.4.2.5.  Antiandrogens

12.4.4.2.6.  Others

12.4.5. Australia

12.4.5.1.  Australia Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.5.1.1.  Combined oral contraceptives

12.4.5.1.2.  Oral contraceptives

12.4.5.1.3.  Injectable contraceptives

12.4.5.1.4.  Implantable contraceptives

12.4.5.1.5.  Intrauterine

12.4.5.1.6.  Transdermal patch

12.4.5.1.7.  Vaginal rings

12.4.5.2.  Australia Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.5.2.1.  Androgen

12.4.5.2.2.  Estrogen

12.4.5.2.3.  Progestogens

12.4.5.2.4.  Gonadotropins

12.4.5.2.5.  Antiandrogens

12.4.5.2.6.  Others

12.4.6. South Korea

12.4.6.1.  South Korea Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.6.1.1.  Combined oral contraceptives

12.4.6.1.2.  Oral contraceptives

12.4.6.1.3.  Injectable contraceptives

12.4.6.1.4.  Implantable contraceptives

12.4.6.1.5.  Intrauterine

12.4.6.1.6.  Transdermal patch

12.4.6.1.7.  Vaginal rings

12.4.6.2.  South Korea Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.6.2.1.  Androgen

12.4.6.2.2.  Estrogen

12.4.6.2.3.  Progestogens

12.4.6.2.4.  Gonadotropins

12.4.6.2.5.  Antiandrogens

12.4.6.2.6.  Others

12.4.7. Southeast Asia

12.4.7.1.  Southeast Asia Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.7.1.1.  Combined oral contraceptives

12.4.7.1.2.  Oral contraceptives

12.4.7.1.3.  Injectable contraceptives

12.4.7.1.4.  Implantable contraceptives

12.4.7.1.5.  Intrauterine

12.4.7.1.6.  Transdermal patch

12.4.7.1.7.  Vaginal rings

12.4.7.2.  Southeast Asia Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.7.2.1.  Androgen

12.4.7.2.2.  Estrogen

12.4.7.2.3.  Progestogens

12.4.7.2.4.  Gonadotropins

12.4.7.2.5.  Antiandrogens

12.4.7.2.6.  Others

12.4.7.3.  Southeast Asia Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

12.4.7.3.1.  Indonesia

12.4.7.3.2.  Thailand

12.4.7.3.3.  Malaysia

12.4.7.3.4.  Singapore

12.4.7.3.5.  Rest of Southeast Asia

12.4.8. Rest of Asia Pacific

12.4.8.1.  Rest of Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

12.4.8.1.1.  Combined oral contraceptives

12.4.8.1.2.  Oral contraceptives

12.4.8.1.3.  Injectable contraceptives

12.4.8.1.4.  Implantable contraceptives

12.4.8.1.5.  Intrauterine

12.4.8.1.6.  Transdermal patch

12.4.8.1.7.  Vaginal rings

12.4.8.2.  Rest of Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

12.4.8.2.1.  Androgen

12.4.8.2.2.  Estrogen

12.4.8.2.3.  Progestogens

12.4.8.2.4.  Gonadotropins

12.4.8.2.5.  Antiandrogens

12.4.8.2.6.  Others

12.5. Key Segment for Channeling Investments

12.5.1. By Country

12.5.2. By Method

12.5.3. By Hormones

13. Middle East and Africa Hormonal Contraceptive Market Analysis and Forecasts, 2019 - 2027

13.1. Overview

13.1.1. Middle East and Africa Hormonal Contraceptive Market Revenue (US$ Mn)

13.2. Middle East and Africa Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

13.2.1. Combined oral contraceptives

13.2.2. Oral contraceptives

13.2.3. Injectable contraceptives

13.2.4. Implantable contraceptives

13.2.5. Intrauterine

13.2.6. Transdermal patch

13.2.7. Vaginal rings

13.3. Middle East and Africa Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

13.3.1. Androgen

13.3.2. Estrogen

13.3.3. Progestogens

13.3.4. Gonadotropins

13.3.5. Antiandrogens

13.3.6. Others

13.4. Middle East and Africa Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

13.4.1. Saudi Arabia

13.4.1.1.  Saudi Arabia Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

13.4.1.1.1.  Combined oral contraceptives

13.4.1.1.2.  Oral contraceptives

13.4.1.1.3.  Injectable contraceptives

13.4.1.1.4.  Implantable contraceptives

13.4.1.1.5.  Intrauterine

13.4.1.1.6.  Transdermal patch

13.4.1.1.7.  Vaginal rings

13.4.1.2.  Saudi Arabia Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

13.4.1.2.1.  Androgen

13.4.1.2.2.  Estrogen

13.4.1.2.3.  Progestogens

13.4.1.2.4.  Gonadotropins

13.4.1.2.5.  Antiandrogens

13.4.1.2.6.  Others

13.4.2. UAE

13.4.2.1.  UAE Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

13.4.2.1.1.  Combined oral contraceptives

13.4.2.1.2.  Oral contraceptives

13.4.2.1.3.  Injectable contraceptives

13.4.2.1.4.  Implantable contraceptives

13.4.2.1.5.  Intrauterine

13.4.2.1.6.  Transdermal patch

13.4.2.1.7.  Vaginal rings

13.4.2.2.  UAE Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

13.4.2.2.1.  Androgen

13.4.2.2.2.  Estrogen

13.4.2.2.3.  Progestogens

13.4.2.2.4.  Gonadotropins

13.4.2.2.5.  Antiandrogens

13.4.2.2.6.  Others

13.4.3. Egypt

13.4.3.1.  Egypt Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

13.4.3.1.1.  Combined oral contraceptives

13.4.3.1.2.  Oral contraceptives

13.4.3.1.3.  Injectable contraceptives

13.4.3.1.4.  Implantable contraceptives

13.4.3.1.5.  Intrauterine

13.4.3.1.6.  Transdermal patch

13.4.3.1.7.  Vaginal rings

13.4.3.2.  Egypt Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

13.4.3.2.1.  Androgen

13.4.3.2.2.  Estrogen

13.4.3.2.3.  Progestogens

13.4.3.2.4.  Gonadotropins

13.4.3.2.5.  Antiandrogens

13.4.3.2.6.  Others

13.4.4. Kuwait

13.4.4.1.  Kuwait Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

13.4.4.1.1.  Combined oral contraceptives

13.4.4.1.2.  Oral contraceptives

13.4.4.1.3.  Injectable contraceptives

13.4.4.1.4.  Implantable contraceptives

13.4.4.1.5.  Intrauterine

13.4.4.1.6.  Transdermal patch

13.4.4.1.7.  Vaginal rings

13.4.4.2.  Kuwait Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

13.4.4.2.1.  Androgen

13.4.4.2.2.  Estrogen

13.4.4.2.3.  Progestogens

13.4.4.2.4.  Gonadotropins

13.4.4.2.5.  Antiandrogens

13.4.4.2.6.  Others

13.4.5. South Africa

13.4.5.1.  South Africa Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

13.4.5.1.1.  Combined oral contraceptives

13.4.5.1.2.  Oral contraceptives

13.4.5.1.3.  Injectable contraceptives

13.4.5.1.4.  Implantable contraceptives

13.4.5.1.5.  Intrauterine

13.4.5.1.6.  Transdermal patch

13.4.5.1.7.  Vaginal rings

13.4.5.2.  South Africa Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

13.4.5.2.1.  Androgen

13.4.5.2.2.  Estrogen

13.4.5.2.3.  Progestogens

13.4.5.2.4.  Gonadotropins

13.4.5.2.5.  Antiandrogens

13.4.5.2.6.  Others

13.4.6. Rest of Middle East & Africa

13.4.6.1.  Rest of Middle East & Africa Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

13.4.6.1.1.  Combined oral contraceptives

13.4.6.1.2.  Oral contraceptives

13.4.6.1.3.  Injectable contraceptives

13.4.6.1.4.  Implantable contraceptives

13.4.6.1.5.  Intrauterine

13.4.6.1.6.  Transdermal patch

13.4.6.1.7.  Vaginal rings

13.4.6.2.  Rest of Middle East & Africa Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

13.4.6.2.1.  Androgen

13.4.6.2.2.  Estrogen

13.4.6.2.3.  Progestogens

13.4.6.2.4.  Gonadotropins

13.4.6.2.5.  Antiandrogens

13.4.6.2.6.  Others

13.5. Key Segment for Channeling Investments

13.5.1. By Country

13.5.2. By Method

13.5.3. By Hormones

14. Latin America Hormonal Contraceptive Market Analysis and Forecasts, 2019 - 2027

14.1. Overview

14.1.1. Latin America Hormonal Contraceptive Market Revenue (US$ Mn)

14.2. Latin America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

14.2.1. Combined oral contraceptives

14.2.2. Oral contraceptives

14.2.3. Injectable contraceptives

14.2.4. Implantable contraceptives

14.2.5. Intrauterine

14.2.6. Transdermal patch

14.2.7. Vaginal rings

14.3. Latin America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

14.3.1. Androgen

14.3.2. Estrogen

14.3.3. Progestogens

14.3.4. Gonadotropins

14.3.5. Antiandrogens

14.3.6. Others

14.4. Latin America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country

14.4.1. Brazil

14.4.1.1.  Brazil Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

14.4.1.1.1.  Combined oral contraceptives

14.4.1.1.2.  Oral contraceptives

14.4.1.1.3.  Injectable contraceptives

14.4.1.1.4.  Implantable contraceptives

14.4.1.1.5.  Intrauterine

14.4.1.1.6.  Transdermal patch

14.4.1.1.7.  Vaginal rings

14.4.1.2.  Brazil Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

14.4.1.2.1.  Androgen

14.4.1.2.2.  Estrogen

14.4.1.2.3.  Progestogens

14.4.1.2.4.  Gonadotropins

14.4.1.2.5.  Antiandrogens

14.4.1.2.6.  Others

14.4.2. Argentina

14.4.2.1.  Argentina Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

14.4.2.1.1.  Combined oral contraceptives

14.4.2.1.2.  Oral contraceptives

14.4.2.1.3.  Injectable contraceptives

14.4.2.1.4.  Implantable contraceptives

14.4.2.1.5.  Intrauterine

14.4.2.1.6.  Transdermal patch

14.4.2.1.7.  Vaginal rings

14.4.2.2.  Argentina Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

14.4.2.2.1.  Androgen

14.4.2.2.2.  Estrogen

14.4.2.2.3.  Progestogens

14.4.2.2.4.  Gonadotropins

14.4.2.2.5.  Antiandrogens

14.4.2.2.6.  Others

14.4.3. Rest of Latin America

14.4.3.1.  Rest of Latin America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method

14.4.3.1.1.  Combined oral contraceptives

14.4.3.1.2.  Oral contraceptives

14.4.3.1.3.  Injectable contraceptives

14.4.3.1.4.  Implantable contraceptives

14.4.3.1.5.  Intrauterine

14.4.3.1.6.  Transdermal patch

14.4.3.1.7.  Vaginal rings

14.4.3.2.  Rest of Latin America Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones

14.4.3.2.1.  Androgen

14.4.3.2.2.  Estrogen

14.4.3.2.3.  Progestogens

14.4.3.2.4.  Gonadotropins

14.4.3.2.5.  Antiandrogens

14.4.3.2.6.  Others

14.5. Key Segment for Channeling Investments

14.5.1. By Country

14.5.2. By Method

14.5.3. By Hormones

15. Competitive Benchmarking

15.1. Brand Benchmarking

15.2. Market Share Analysis, 2018

15.3. Global Presence and Growth Strategies

15.3.1. Mergers and Acquisitions

15.3.2. Product Launches

15.3.3. Investments Trends

15.3.4. R&D Initiatives

16. Player Profiles

16.1. Allergan

16.1.1. Company Details

16.1.2. Company Overview

16.1.3. Product Offerings

16.1.4. Key Developments

16.1.5. Financial Analysis

16.1.6. SWOT Analysis

16.1.7. Business Strategies

16.2. Bayer Pharmaceuticals

16.2.1. Company Details

16.2.2. Company Overview

16.2.3. Product Offerings

16.2.4. Key Developments

16.2.5. Financial Analysis

16.2.6. SWOT Analysis

16.2.7. Business Strategies

16.3. Cipla

16.3.1. Company Details

16.3.2. Company Overview

16.3.3. Product Offerings

16.3.4. Key Developments

16.3.5. Financial Analysis

16.3.6. SWOT Analysis

16.3.7. Business Strategies

16.4. Merck and Co., Inc.

16.4.1. Company Details

16.4.2. Company Overview

16.4.3. Product Offerings

16.4.4. Key Developments

16.4.5. Financial Analysis

16.4.6. SWOT Analysis

16.4.7. Business Strategies

16.5. Novartis

16.5.1. Company Details

16.5.2. Company Overview

16.5.3. Product Offerings

16.5.4. Key Developments

16.5.5. Financial Analysis

16.5.6. SWOT Analysis

16.5.7. Business Strategies

16.6. Piramal pharma Solutions

16.6.1. Company Details

16.6.2. Company Overview

16.6.3. Product Offerings

16.6.4. Key Developments

16.6.5. Financial Analysis

16.6.6. SWOT Analysis

16.6.7. Business Strategies

16.7. Teva Pharmaceutical Industries Ltd

16.7.1. Company Details

16.7.2. Company Overview

16.7.3. Product Offerings

16.7.4. Key Developments

16.7.5. Financial Analysis

16.7.6. SWOT Analysis

16.7.7. Business Strategies

16.8. Other Market Participants

17. Key Findings

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 163

    Backtrace:

    File: /var/www/html/ami/application/views/pages/reportpage.php
    Line: 163
    Function: _error_handler

    File: /var/www/html/ami/application/controllers/Report.php
    Line: 153
    Function: view

    File: /var/www/html/ami/index.php
    Line: 315
    Function: require_once